Enoximonum
Enoximonum Uses, Dosage, Side Effects, Food Interaction and all others data.
Enoximonum is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with congestive heart failure. Trials were halted in the U.S., but the drug is used in various countries.
Enoximonum is a phosphodiesterase inhibitor (type III) that increases the force of contraction of the heart and dilates blood vessels. In June 2005, Myogen announced that they were discontinuing development of enoximone due to negative results. The drug is approved for use in the UK.
Trade Name | Enoximonum |
Generic | Enoximone |
Enoximone Other Names | Enoximona, Enoximone, Enoximonum |
Type | |
Formula | C12H12N2O2S |
Weight | Average: 248.301 Monoisotopic: 248.061948328 |
Protein binding | 85% |
Groups | Approved, Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Enoximonum is a selective phosphodiesterase inhibitor indicated in the short term treatment of congestive heart failure.
For the treatment of congestive heart failure.
Enoximonum is also used to associated treatment for these conditions: Congestive Heart Failure (CHF)
How Enoximonum works
Further research is required to determine accurately the mechanism of action of drugs with phosphodiesterase inhibitory activity, however, inhibition of PDE3 inhibits degredation of cGMP. This allows for increased NO release and vascular relaxation.
Elimination Route
Bioavailabvility is 50% following oral administration.
Half Life
4-10 hours
Innovators Monograph
You find simplified version here Enoximonum